Sugi Predict

Sugi Predict / Compounds / SCHEMBL4120545

SCHEMBL4120545

SCHEMBL4120545

CC(C)(C)OC(=O)N[C@H]1C[C@H](OC(=O)c2ccccc2)CN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 1/20 0.48
▸ KMT2A Q03164 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ HSD11B1 P28845 2/20 0.46
▸ SYK P43405 1/20 0.40
▸ CHRM4 P08173 1/20 0.40
▸ USP30 Q70CQ3 2/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ RORC P51449 1/20 0.40
▸ HTT P42858 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ PDK1 Q15118 1/20 0.39
▸ PDK2 Q15119 1/20 0.39
▸ PDK3 Q15120 1/20 0.39
▸ PDK4 Q16654 1/20 0.39
▸ KDM1A O60341 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4131437 0.88 PDE4B (0.53) PDE4BKMT2AL3MBTL1HSD11B1SYK
SCHEMBL20498564 0.88 PDE4B (0.53) PDE4BKMT2AL3MBTL1HSD11B1SYK
SCHEMBL376879 0.88 PDE4B (0.53) PDE4BKMT2AL3MBTL1HSD11B1SYK
SCHEMBL13456796 0.88 KMT2A (0.55) PDE4BKMT2AL3MBTL1HSD11B1SYK
SCHEMBL14428325 0.88 KMT2A (0.55) PDE4BKMT2AL3MBTL1HSD11B1SYK
SCHEMBL2692835 0.86 KMT2A (0.45) KMT2AL3MBTL1HSD11B1USP30CYP2C9
SCHEMBL23113584 0.86 PDE4B (0.49) PDE4BKMT2AL3MBTL1HSD11B1SYK
SCHEMBL23113583 0.86 PDE4B (0.49) PDE4BKMT2AL3MBTL1HSD11B1SYK
SCHEMBL2821598 0.86 PDE4B (0.54) PDE4BKMT2AL3MBTL1HSD11B1SYK
SCHEMBL11978265 0.84 KMT2A (0.51) PDE4BKMT2AL3MBTL1HSD11B1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022123-A1 Methods of Making Modified BTK Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2026-01-22 — — US disclosed
US-8829193-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-09 — — US disclosed
EP-2262802-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-10-23 — — EP disclosed
US-8168794-B2 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-05-01 — — US disclosed
US-20100216839-A1 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-26 — — US disclosed
WO-2009109576-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2009-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022123-A1 Methods of Making Modified BTK Inhibitors BTK, TEC, SYK PDE4B 1753/4885KMT2A 655/4885L3MBTL1 1987/4885
US-20100216839-A1 Pim kinase inhibitors and methods of their use PIM1, PIM2, PIM3 PDE4B 1716/4885KMT2A 1446/4885L3MBTL1 1858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.